SITC Hosts "Using Spatial Biology to Monitor Tumor Immune Interactions: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 17 days ago
On November, 13, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the ninth computational immuno-oncology webinar of series 5. This webinar reviewed some methods for extracting information on the tumor immune microenvironment from spatial imaging and spatial genomics assays. It also explored methods that relate the information obtained from different spatial assay types. View the webinar ...
0 comments

Thank You to Our SITC Advocacy Day Volunteers

By SITC Advocacy posted 30 days ago
On Nov. 5, 2025, dedicated volunteers from across the country joined us in Washington, DC, bringing their passion, expertise, and personal stories to the heart of our nation’s capital. Together, they met with numerous congressional offices to share how federal investment in cancer immunotherapy is changing lives, driving new treatments, supporting scientists, and bringing hope to patients and families everywhere. Their voices carried the momentum ...
0 comments

SITC Hosts "Liquid Biopsy Approaches for Cancer Diagnosis and Monitoring: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 10-22-2025
On October 16, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the eighth computational immuno-oncology webinar of series 5. In this webinar, attendees explored the transformative potential of liquid biopsy approaches in cancer characterization, residual disease tracking and therapy response monitoring. Focusing on analyses of circulating tumor DNA (ctDNA), they reviewed how liquid ...
0 comments

SITC Hosts "Unlocking the Power of Spatial Omics with AI: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 09-18-2025
On September 10, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the seventh computational immuno-oncology webinar of series 5. Spatial omics technologies have revolutionized cancer research, but their high cost, long turnaround times, and limited tissue capture areas have hindered widespread adoption.This webinar discussed how AI can unlock the full potential of spatial omics, driving ...
0 comments

SITC Hosts "Assessing the Tumor Microenvironment with Systems Immunology: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 08-28-2025
On August 21, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the sixth computational immuno-oncology webinar of series 5. This webinar dove into how understanding the diverse states of cancer and tumor microenvironment (TME) cells, and their spatial and temporal interactions, is essential for advancing immuno-oncology research. This webinar delved into how computational science and ...
0 comments

SITC Hosts "Predicting Patients' Response to Immunotherapy from Tumor Histopathology and Blood: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 07-15-2025
On July 8, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the fifth computational immuno-oncology webinar of series 5. This webinar described four approaches for predicting patients’ response to checkpoint immunotherapy recently developed in Dr. Ruppin’s lab, including: (1) predicting patients’ response to the tumor bulk transcriptome, (2) predicting response directly from the blood ...
0 comments

SITC Hosts "Non-invasive Biomarkers for irAEs: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 06-25-2025
On June 18, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the fourth computational immuno-oncology webinar of series 5. The webinar was structured in three parts: (1) An overview of the current landscape of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapy; (2) a review of the progress made to date in identifying and defining biomarkers for ...
0 comments

SITC Hosts "Lessons from the CIMAC-CIDC Network: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 06-04-2025
The focus of this webinar on May 29th, 2025 was exploring how machine learning-driven modeling of multimodal data can be used to profile patient heterogeneity and analyze diverse immunotherapy treatments, enabling the identification of cellular and molecular markers linked to clinical outcomes. View the webinar for FREE on-demand HERE .
0 comments

SITC Hosts "Guidelines and Best Practices on Designing Clinical Trials with Exploratory Surrogate Endpoints and CDX: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 05-15-2025
This webinar on May 8th discussed how exploratory surrogate endpoints and companion diagnostics (CDX) are transforming clinical trial design in immuno-oncology, crucial for advancing personalized medicine. By incorporating these innovative approaches, researchers can gain early insights into treatment efficacy, enhancing the likelihood of successful drug approval. Join us to explore how these guidelines and best practices can shape the future of clinical ...
0 comments

SITC Thanks Members for Participating in Their 2025 Capitol Hill Visits!

By SITC Advocacy posted 05-01-2025
SITC’s 2025 Capitol Hill Visits have officially concluded after engaging with over 25 congressional offices! During these meetings, SITC members passionately advocated for the inclusion of SITC’s FY26 appropriations language, emphasizing the need for utilizing novel technologies to advance the field’s understanding of the tumor microenvironment and AI’s potential for developing next generation immunotherapies. We extend our sincere thanks to all ...
0 comments

SITC Statement on Major Staff Reductions at the Department of Health and Human Services

By SITC Advocacy posted 04-30-2025
Dear SITC Members, The Society for Immunotherapy of Cancer (SITC) strongly opposes the recent actions asking for a significant reduction in staff at the Department of Health and Human Services (HHS). As an organization dedicated to advancing the science and application of cancer immunotherapy to make the word "cure" a reality for patients, SITC is deeply concerned that these cuts are already resulting in profound and detrimental impact on the ...
0 comments

SITC’s 2025 Capitol Hill Visits!

By SITC Advocacy posted 04-29-2025
SITC is pleased to announce the kickoff of SITC’s 2025 in person Capitol Hill Visits! Over the last few months SITC members have been meeting virtually with congressional offices all across the country to advocate for inclusion of SITC’s FY26 appropriations language aimed at utilizing novel technologies to advance the field’s understanding of the tumor microenvironment and AI’s potential for developing next generation immunotherapies. These meetings ...
0 comments

SITC Hosts Advanced Biomarker Development and Clinical Translation: Computational Science in Immuno-oncology Webinar

By SITC Advocacy posted 04-09-2025
This webinar on April 2 explored what b iomarker discovery for cancer immunotherapy entails using high-dimensional multi- omic assays that can be difficult to interpret, particularly in the setting of challenging clinical trial designs such as small cohort size or unbalanced response rates. This webinar therefore addressed advances in computational science and biostatistics that allow for rigorous interpretation of complex exploratory biomarker ...
0 comments

Announcing the publication of “Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols”

By SITC Advocacy posted 03-26-2025
The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a comprehensive manuscript, “Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols” in the Journal for ImmunoTherapy of Cancer (JITC). This work provides an in-depth examination of evidence-based biomarkers that measure the potential for therapeutic response and/or toxicity are critical ...
0 comments

Kick-off of SITC’s 2025 Capitol Hill Visits!

By SITC Advocacy posted 03-03-2025
SITC is pleased to announce the kickoff of SITC’s 2025 Capitol Hill Visits! SITC members are meeting with congressional offices to advocate for inclusion of SITC’s FY26 appropriations language aimed at utilizing novel technologies to advance the field’s understanding of the tumor microenvironment and AI’s potential for developing next generation immunotherapies. SITC members are also sharing with their representatives our recent statement regarding ...
0 comments

SITC Statement on NIH to Indirect Costs

By SITC Advocacy posted 02-19-2025
SITC released a statement addressing their concerns for the recent announcement from the National Institutes of Health (NIH) that will cut billions of dollars in indirect costs for current and future grants to research institutions across the U.S. Read the full statement and find out how to push back against cuts to NIH indirect costs here .
0 comments

SITC Participates in Sign on Letter to Support the AKACA

By SITC Advocacy posted 12-11-2024
SITC has recently signed on to a letter from the Leukemia Lymphoma Society advocating congress to pass the Accelerating Kids Access to Care Act (AKACA). SITC joined 230 other organizations in supporting this important piece of legislation. More information on the bill as well as the final letter can be found at this LINK . #Letter #Policy
0 comments

SITC Hosts Tumor Biomarkers and Assessing PD-1: Increasing Access to IO Webinar

By SITC Advocacy posted 12-04-2024
This webinar on November 21st examined how biomarkers are used to define “PD-L1” positive patients around the globe and in resource limited settings. It provided a forum for physicians to discuss their experience assessing different criteria, as well as the solutions that were implemented to overcome specific challenges. Additionally, this topic reviewed the global availability of different platforms/clones and tumor mutational burden (TMB). View ...
0 comments

Annual Meeting Session Highlight: Cellular Therapies/Regulatory/Manufacturing

By SITC Advocacy posted 11-06-2024
Cellular therapies offer great promise as a cancer therapy. They are living biological drugs, and often personalized, which gives them unique properties, characteristics, and great variability. These factors have made adhering to existing regulatory requirements challenging and requires significant collaboration and interactions with the FDA and other health authorities. Commercializing approved cellular therapies requires novel strategies for adoption, ...
0 comments

Tumor Infiltrating Lymphocytes (TIL) Symposium

By SITC Advocacy posted 11-04-2024
As part of the 39th Annual Meeting & Pre-Conference Programs (SITC 2024), the SITC Tumor Infiltrating Lymphocytes (TIL) Symposium pre-conference program provides an opportunity for an in-depth discussion on a specific topic in the field of IO. This program will provide an overview of the path to approval for TIL therapy, current clinical management, and the impact of recent FDA-approved therapies while exploring next generation TIL and innovative ...
0 comments